Full Text View
Tabular View
No Study Results Posted
Related Studies
Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis
This study has been terminated.
( Administratively complete. )
Study NCT00030381   Information provided by National Cancer Institute (NCI)

First Received on February 14, 2002.   Last Updated on January 15, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Primary Systemic Amyloidosis
Additional conditions recognized in this trial
Amyloidosis
More general conditions related to this trial
Metabolic Diseases
Proteostasis Deficiencies
Interventions listed in this trial
4'-iodo-4'-deoxydoxorubicin
pharmacological study
Additional drug interventions recognized in this trial
4'-deoxydoxorubicin
Doxorubicin
More general drug interventions related to this trial
Antibiotics, Antineoplastic
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services